CTOs on the Move

Mustang Bio

www.mustangbio.com

 
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.mustangbio.com
  • 2 Gansevoort Street 9th Floor
    New York, NY USA 10014
  • Phone: 781.652.4500

Executives

Name Title Contact Details
Knut Niss
 Chief Technology Officer Profile

Funding

Mustang Bio raised $20M on 04/01/2019
Mustang Bio raised $75M on 03/08/2022

Similar Companies

Dove Management Resources

Dove Management Resources is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centric Health Resources

Centric Health Resources is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AN2 Therapeutics

AN2 Therapeutics is a biopharmaceutical company that develops therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.

Balance Autism

Balance Autism is a leading autism service organization in Iowa.

Cellectis

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.